Organon & Co. (NYSE:OGN) Shares Gap Down to $20.19

Organon & Co. (NYSE:OGN) shares gapped down prior to trading on Tuesday . The stock had previously closed at $20.19, but opened at $19.58. Organon & Co. shares last traded at $18.91, with a volume of 100,950 shares traded.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Piper Sandler lifted their target price on Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, April 29th. The Goldman Sachs Group raised their target price on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd.

Organon & Co. Price Performance

The company has a quick ratio of 1.15, a current ratio of 1.65 and a debt-to-equity ratio of 181.35. The company has a market cap of $4.89 billion, a price-to-earnings ratio of 4.51, a price-to-earnings-growth ratio of 1.01 and a beta of 0.85. The company has a fifty day simple moving average of $20.87 and a two-hundred day simple moving average of $19.26.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Atomi Financial Group Inc. grew its stake in Organon & Co. by 1.8% in the first quarter. Atomi Financial Group Inc. now owns 32,858 shares of the company’s stock valued at $618,000 after purchasing an additional 593 shares in the last quarter. Bill Few Associates Inc. boosted its holdings in Organon & Co. by 5.4% during the second quarter. Bill Few Associates Inc. now owns 12,218 shares of the company’s stock worth $253,000 after purchasing an additional 621 shares during the last quarter. GAMMA Investing LLC raised its stake in Organon & Co. by 19.2% in the second quarter. GAMMA Investing LLC now owns 4,036 shares of the company’s stock valued at $84,000 after buying an additional 649 shares during the period. Benedetti & Gucer Inc. boosted its holdings in shares of Organon & Co. by 3.4% during the first quarter. Benedetti & Gucer Inc. now owns 20,245 shares of the company’s stock worth $381,000 after acquiring an additional 670 shares during the period. Finally, Signaturefd LLC raised its position in shares of Organon & Co. by 6.6% in the second quarter. Signaturefd LLC now owns 11,308 shares of the company’s stock valued at $234,000 after buying an additional 698 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.